iPSC-derived NK cell therapies at AACR22

Companies and institutions are showcasing ways to increase persistence and efficacy of NK cell therapies at AACR22, with a focus on iPSC-derived cells, gene editing and CAR innovation.

Naturally allogeneic NK cells are emerging as safe and effective off-the-shelf cell therapies for both hematologic and solid tumors, but exhaustion due to local immunosuppression can limit tumor killing, and companies are identifying ways to push past the limitation...